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ABSTRACT
Objective: This work is aimed to formulate and evaluate alginate-chitosan microspheres of glipizide for the effective use in the treatment of diabetes.
Methods: Sustained release (SR) microspheres were prepared by gentle mixing of polymers in water with the drug by agitation. The polymers used 
were sodium alginate and chitosan, which was extruded into 5% calcium chloride solution to produce microspheres by ionic gelation method.
Results: Single unit dosage form of glipizide causes gastric irritation. When converted into the multiple unit dosage forms, it will release the drug 
evenly throughout the stomach causing suppression of irritation. The aim of the study was to formulate and evaluate alginate-chitosan microspheres, 
for SR of the chosen drug. The particle size of microspheres was in the range of 200-500 µ, maximum mucoadhesive property observed was 88.2±0.50% 
for formulation GCS7, maximum swelling index was 27.0% for GCS7, and the maximum entrapment was 89.1±0.28% for GCS6 formulation. It showed 
better in-vitro release between 80% and 90% for GCS1 and GCS2 formulation and in formulation GCS3, 50-60% reduction in plasma glucose level 
than conventional dosage forms when tested in-vivo. The work also aims to study various parameters affecting the behavior of microspheres in oral 
dosage form.
Conclusion: Drugs with short half life that are absorbed from the gastrointestinal tract (GIT) are eliminated rapidly from the blood flow. To avoid 
this, the oral SR was developed as this formulation released the drug slowly into the GIT and maintained a stable drug concentration in the serum for 
a longer duration of time.
Keywords: Glipizide, Sodium alginate, Chitosan, Sustained release microspheres, Scanning electron microscopy, Differential scanning calorimetry, 
In-vitro and in-vivo activity.
INTRODUCTION
The drug delivery systems that can precisely control the release rates 
or target drugs to specific body site have an enormous impact on the 
health-care system. The past two decades have witnessed an avant-
garde interaction among the field of polymer and material science, 
resulting in the development of novel drug delivery systems [1]. 
Microspheres acquire important features among the particulate drug 
delivery systems by virtue of their small size and efficient carrier 
characteristics. However, the success of microspheres delivery system 
is less due to their short residence time at the site of absorption [2]. The 
physicochemical characteristics of the active chosen vary considerably, 
so microspheres are often developed according to specific clinical 
needs [3]. Microspheres were prepared by the emulsion-gelation 
method for their ease and cost-effectiveness [4].
Diabetes mellitus (DM) is a chronic metabolic disorder affecting people 
worldwide, with significant morbidity and mortality caused by its 
microvascular and macrovascular complications, affecting various vital 
organs and structures in humans [5]. It has been estimated that by 
the year 2030, the diabetic population will rapidly increase. However, 
prevalence is much more, as many patients are asymptomatic and go 
undiagnosed. Glipizide is an antidiabetic drug used to treat Type II 
DM. Glipizide with a half life of 2-3 hrs was converted in sustained 
release (SR) formulation to reduce dosing frequency. A model dosage 
form is one, which attains the desired therapeutic concentration of 
drug in plasma and maintains it for the entire duration of treatment. 
The absorption of glipizide is reduced, when taken after meals hence 
are advised to be taken on an empty stomach. The sustain release 
formulations of this drug results in constant plasma level for up to 
24 hrs [6]. It is extensively metabolized (90%) by the liver and only 
10% excreted unchanged by the kidney [7].
Glipizide
Glipizide is an oral blood glucose-lowering drug of the sulfonylurea class, 
chemical name is l-cyclohexyl-3-[[p-[2-(5-methyrpyrazine-carboxamido) 
ethyl]phenyl]sulfonyl]urea [8]. It is a whitish, odorless powder, insoluble 
in water and alcohols, but soluble in 0.1 N NaOH, and freely soluble in 
dimethylformamide. Its molecular formula is C21H27N5O4S, the molecular 
weight is 445.55, the melting point is 195-200°C and pKa is 5.9 [9]. The 
chemical structure of glipizide shown in Fig. 1.
In this investigation, a formulation of glipizide, capable of providing 
detectable blood levels over 10 hrs was formulated using expandable, 
gelling, and swellable hydrocolloid polymer. The polymer used was 
sodium alginate, which is an inexpensive, nontoxic product extracted 
from kelp of brown algae. Alginic acid, also called algin or alginate, 
is an anionic polysaccharide distributed widely in the cell walls of 
brown algae, which on binding with water forms a viscous gum. It is 
capable of absorbing 200-300 times of water. Alginates refined from 
different species of brown seaweed have variations in their chemical 
structure, resulting in different physical properties. Some may yield an 
alginate that gives a strong gel, some a weaker gel; some may readily 
give a cream/white alginate, while some with difficulty and is best 
used for applications where color does not matter. Sodium alginate 
has been used as a thickening and gelling agent and because it reduces 
interfacial tension between an oil and water phase, it is used for the 
preparation of emulsion also. Alginate is a linear copolymer composed 
of two monomeric units, D-mannuronic acid, and L-guluronic acid. 
These monomers occur in the alginate molecule as regions made 
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up exclusively of one unit or the other, referred to as M-blocks or 
G-blocks, or as regions in which the monomers forms an alternating 
sequence. The calcium reactivity of alginates is a consequence of the 
particular molecular geometries of each of these regions [10]. Sodium 
alginate is capable of forming rigid gels by the action of calcium ion or 
multivalent cations. It is relatively easy to describe alginates in terms 
of M and G units, but the detailed molecular compositions of alginates 
in terms of block lengths and block distributions are quite difficult to 
determine [11].
The chitosan entrapped calcium pectinate microspheres have been 
used for SR of drugs or for targeting drugs to the colon [12].
METHODS
Glipizide was obtained as a gift sample from by Kreative Organics, 
Hyderabad. Chitosan from Kerala State chitosan plant, Kerela, and 
sodium alginate was purchased from CDH, New Delhi. All other 
chemicals used were of analytical grade.
Preparation of microspheres
Glipizide chitosan-alginate microspheres
The required quantity of sodium alginate was dissolved in distilled 
water (30 ml). Calculated quantity of the drug was added and 
homogenized. Chitosan in required proportion was dissolved in 2% v/v 
acetic acid with pH (5.5) adjusted with 10% NaOH solution. 5% calcium 
chloride dehydrate solution was added to it. Drug alginate mixture was 
added to the chitosan-calcium chloride solution dropwise at a constant 
rate of 30 ml/h with gentle stirring over thermal controlled magnetic 
stirrer. The formed microspheres were filtered, washed with acetone 
and dried in an oven at 35°C. The dried formulations were stored in an 
amber colored bottle and kept in a desiccator until used (Table 1).
Percentage yield
The percentage yield of the microspheres was calculated for each batch 
by dividing the weight of microspheres by the total weight of drug and 
polymer.
Percentage yield=Practical yield/theoretical yield × 100
Size distribution and size analysis
Glipizide chitosan microspheres were separated into different size 
fractions by sieving for 10 minutes using a mechanical shaker containing 
standard sieves as per Indian Pharmacopeia specifications. The particle 
size distribution was determined and means particle size of gel beads 
was calculated by the following formula and shown in Fig. 2.
( )
Mean particle size of the fraction








Differential scanning calorimetry (DSC)
Thermograms of drug, polymers, and microspheres were obtained 
using DSC 822e (Mettler Toledo) calorimeter. DSC measures the 
amount of heat energy absorbed or released by a sample, as it is heated, 
cooled or held at a constant temperature. Thermogram shows that no 
interaction seen between polymers and also between the polymer and 
drug. The drugs and polymers showed separate peaks in thermogram 
(Fig. 3).
Scanning electron microscopy (SEM)
The samples for the SEM analysis were prepared by sprinkling the 
microspheres on one side of the double adhesive stub. The stub was 
then coated with fine gold dust. The microspheres were then observed 
under the SEM (JEOL Model JSM-6390LV) at 15 kV. It showed discreet, 
more and less uniform and uniformly distributed microspheres (Fig. 4).
Entrapment efficiency
The prepared microspheres were dissolved, and the amount of 
drug present in weighed samples was determined by analyzing 
spectrophotometrically at 276 nm after filtration and suitable 
dilutions [13]. The method obeyed Beer’s law in the concentration 
range of 0-35 µg/ml. The entrapment efficiency was calculated from the 
theoretical amount and actual amount of the drug in dry microspheres.
Drug entrapment efficiency (%)=Calculated drug content/theoretical 
drug content × 100
Swelling index
Swelling index was determined by measuring the extent of swelling 
of microspheres in a particular buffer solution. To ensure complete 
equilibrium weighed, the amount of microspheres was allowed to 
swell in a buffer solution. The excess liquid adhering to the drops were 
removed by blotting, and the swollen microspheres were weighed using 
microbalance. The hydrogel microspheres were then dried in an oven at 
60°C for 5 hrs until there was no change in the dried mass of the sample. 
The swelling index of the microsphere was calculated by the following 
formula [14].





Table 1: Formulation process codes and parameter for the 
formulation of the glipizide microspheres by ionic gelation 
method
Alginate-chitosan microspheres





GCS1 100 mg + + 30 ml 100 ml 1:0.5
GCS2 + + + + + 1:1
GCS3 + + + + + 1:1.2
GCS4 + + + + + 1:1.4
GCS5 + + + + + 1:1.6
GCS6 + + + + + 1:1.8
GCS7 + + + + + 1:2
D:P: Drug to polymer ratio, +: Present
Fig. 1: Chemical structure of glipizide
Fig. 2: Size distribution of sodium alginate microspheres of drug 
glipizide (Drug to polymer-1: 0.5-1:2)
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Mucoadhesive studies
Approximately 50 microspheres were taken and spread uniformly 
over a wet glass slide, which was held to the walls of the beaker with 
glue. This assembly was then introduced into the USP disintegration 
apparatus. A number of microspheres still adhering to the glass slide 
was counted at regular intervals and assessed for the mucoadhesive 
nature of the microspheres. All the readings were taken in triplicate and 
results depicted in±standard deviation (SD) (Table 2).
In-vitro release studies
Preparation of standard plot in methanol
Glipizide (50 mg) was dissolved in 100 ml of methanol. It was then 
suitably diluted for graded solutions in a range of 0-35 µg/ml. The 
absorbance was read using an ultraviolet (UV) spectrophotometer 
(Shimadzu 1800) at λmax 276 nm (Table 3 and Fig. 5).
In-vitro release of microspheres
The in-vitro release studies were conducted at 37±0.5°C and at 100 rpm 
by buffer change method using 0.1 N HCl (1 hrs), 4 pH (1 hrs), 6 pH 
(3 hrs), 6.8 pH (3 hrs), and 7.4 pH (2 hrs) phosphate buffers (200 ml) 
in sink conditions using a diffusion cell. Accurately weighed sample 
of prepared microspheres was added to the donor cell. At preset time 
intervals; 5 ml of aliquots were withdrawn and replaced by an equal 
volume of fresh dissolution medium. The aliquots were analyzed UV 
spectrophotometrically at λmax 276 nm after proper dilution (Table 4 
and Fig. 6).
In-vivo hypoglycemic activity
In-vivo hypoglycemic activity of Glipizide formulation, in normal 
and hyperglycemic rats
The in-vivo hypoglycemic activity was conducted in healthy and 
hyperglycemia-induced male albino Wistar rats of 175±25 g body 
weight by measuring the hyperglycemic effect produced after oral 
administration of a microspheres dose equivalent to 5 mg/kg body 
weight of glipizide in comparison to the pure drug at the same dose.
All animal experiments were approved by Institutional Animal Ethics 
Committee (IAEC) of Pinnacle Biomedical Research Institute (PBRI) 
Bhopal (Reg. No. 1824/PO/ERe/S/15/CPCSEA). Protocol Approval 
Reference No. PBRI/IAEC/PN-16042. Animals were housed in separate 
cages under controlled conditions of temperature (22±2°C). All 
animals were given standard diet (golden feed, New Delhi) and water 
regularly [15].
Fig. 3: Differential scanning calorimetry of glipizide alginate-chitosan microspheres (GCS-4)
Fig. 4: Scanning electron microscopy of GCS-7
Fig. 5: Standard plot of glipizide in methanol
Fig. 6: In-vitro drug release of GCS1-GCS7
Animals were kept at 12 hrs in alternating light and dark cycles. Animals 
were further divided into eight groups with six animals in each group 
(Table 5) [16].
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Induction of diabetes
1. Diabetes was induced in rats by intraperitoneal injection of 
streptozotocin (STZ) at a dose of 60 mg/kg body weight. STZ 
dissolved in ice cold 0.1 M citrate buffer
2. The animals were allowed to drink 5% glucose solution overnight 
to overcome STZ induced hyperglycemia
3. The animals were considered as diabetic, if their blood glucose value 
was above 200 mg/dl on the 3rd day of STZ injection
4. The treatment was started on the 4th day after the STZ injection, 
considering it as the 1st day of treatment. The treatment was 
continued till 7 days
5. Blood glucose level and body weight were observed on 0, 3, 5, and 
7th day of post-treatment (Table 6).
Experimentation
All animals were divided randomly into six groups with six 
animals in each group. Group I, received normal saline orally only 
and served as vehicle control, Groups II, III, IV, V, VI, and VII were 
made diabetic with STZ. Group II received saline, Groups III and IV 
received glipizide (5 mg/kg) per day oral, Groups V, VI, and VII 
received formulation GCS3 (5 mg/kg) per day oral. All dosing of test 
samples was done orally throughout the experimentation (Table 7 
and Fig. 7).
Stability studies of formulations
Stability testing is an integral part of the formulation development. 
It generates information about the shelf life of drug substances and 
their formulations and recommends appropriate guidelines for 
storage [17,18]. In the formulations GCS1-GCS7, there was no significant 
change in stability. Loss of drug content was seen in formulations with 
low polymer concentrations.
Morphological characteristics and release profile
The formulated microspheres were stable throughout the course of 
study of about (90 days) at 5°C in the freezer, at room temperature 
(32°C) and at 45°C in oven [19,20]. There was no significant 
morphological change or changes in release characteristics. Slight 
color changes were observed at elevated temperature because of 
degradation of polymers.
RESULT AND DISCUSSION
The effects of process variables on various physicochemical, 
morphological and in-vitro release characteristics were studied. The low 
coefficient of variations showed that the method is highly reproducible.
Microspheres of glipizide were formulated using sodium alginate and 
chitosan by orifice ionic gelation method. Different concentrations of 
the polymer were used to entrap the drug, and various process variable 
parameters were analyzed.
The microspheres were discrete, free flowing and monolithic matrix 
type. A coat of chitosan was also produced on the surface of the alginate 
microparticles.
The mucoadhesive property of the microspheres increased with 
increase in the concentration of polymer. The size distribution was in 
the range of 200-500 µm. It was observed that increase in the polymer 
ratio, increased the size of the microspheres. Incorporation of more 
polymers resulted in increased size due to the distribution of the 
insoluble drugs in the interstitial spaces of the matrix.
It was observed that higher proportion of polymer in the formulation 
resulted in the microspheres being smoother. The drug release rate 
decreased with increase in chitosan concentration. Microspheres 
showed the inherent brown color of the polymers. When the proportion 
of polymer was increased, the percentage yield and the drug entrapment 
also improved.
Drug release characteristics were studied in simulated gastric and 
intestinal fluid without pepsin to simulate the gastrointestinal 
environment. Release was slow and uniformly spread over a period of 
time. This could be attributed to the matrix nature of the formulation. 
Poor water soluble drugs seem to rush initially into the interstitial 
spaces of the polymer, from where the water phase forces the drug into 
the gel portion of the polymer. The swelling hydrophilic membrane then 
acts as a flux controlling barrier [21,22]. Thus, alginate microspheres 
with chitosan, prepared by simple ionic gelation method, could be used 
for sustain release of the drug [23]. The drug release was diffusion as 
well as erosion controlled.
Table 2: Physicochemical properties of the glipizide chitosan-alginate microspheres (D:P-1: 0.5-1:2), n=3
Chitosan-alginate microspheres of glipizide
Code % yield % entrapment±SD Shape Color % Swelling index Mucoadhe. property (%)±SD
GCS1 90.6 87.1±0.10 Spherical Light brown 11.5 49.1±0.60
GCS2 85.2 84.4±0.15 Spherical Light brown 15.7 63.0±1.50
GCS3 84.3 89.6±0.10 Spherical Light brown 17.2 65.2±1.14
GCS4 92.0 88.4±0.10 Spherical Light brown 19.0 69.5±1.52
GCS5 91.1 72.1±0.07 Spherical Light brown 20.5 72.5±0.45
GCS6 85.1 89.1±0.28 Spherical Light brown 24.5 81.3±0.43
GCS7 83.3 82.0±0.10 Spherical Light brown 27.0 88.2±0.50
SD: Standard deviation
Table 3: Glipizide pure drug absorbance in UV 
spectrophotometer










Fig. 7: % reduction in plasma glucose level in hyperglycemic rats 
after administration of pure drug and formulation GCS3
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Statistical analysis of in-vivo data
All data were analyzed by one-way ANOVA followed by Bonferroni 
test. p<0.05 was considered as the level of significance. All data are 
presented in mean±SD.
Glipizide showed a significant decrease in plasma glucose levels in both 
normal and hyperglycemic rats.
A 25% reduction in glucose is considered a significant hypoglycemic 
effect. The sustained hypoglycemic effect with microspheres is due to 
the slow release and absorption of glipizide over extended periods of 
time.
The plasma glucose level of diabetic controlled rats increased 
significantly from day 3 to day 7 of STZ injection. Hyperglycemic rats 
were selected for the study as discussed above. The plasma glucose 
data obtained indicates that the drug is entrapped in microspheres 
and produced the consistent antihyperglycemic effect. This effect was 
pronounced in the case of hyperglycemic rats whereas normal rats 
showed comparatively lesser alterations in plasma glucose level after 
formulation administration.
CONCLUSION
A new SR system of glipizide microspheres of alginate-chitosan was 
designed and formulated by an ionic gelation method. It’s morphological, 
and release characteristics were studied. The microspheres were 
easy to prepare, and the mean diameter of microspheres increased 
with increase in the amount of the polymers increase. The pore size 
of microspheres was affected by the concentration of the alginate and 
chitosan. Stirring at high speed above 200 rpm causes the destruction of 
microspheres. The microspheres showed excellent in-vivo activity and 
SR characteristics as compared to the conventional oral dosage forms. 
Thus, drug entrapment technique is a useful tool for the development of 
multiparticulate system even for a water-insoluble drug.
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